Supernatants obtained by degranulation of dog mastocytoma cells greatly increased the sensitivity and the magnitude of the contractile response of isolated dog bronchial smooth muscle to histamine. The enhanced contractile response was reversed completely by H1-receptor antagonists and was prevented by an inhibitor of tryptase (a major protease released with histamine from secretory granules of mast cells). The potentiation of histamine-induced contractions was reproduced by active tryptase in pure form. The contractions due to the combination of histamine and purified tryptase were abolished by the Ca2+ channel blockers nifedipine and verapamil. The bronchoconstricting effects of KCl and serotonin, which, like histamine, contract airway smooth muscle by a mechanism predominantly involving membrane potential-dependent Ca2+ transport, were also potentiated by tryptase. However, the contractile effects of acetylcholine, which contracts dog airway smooth muscle by a mechanism independent of Ca2+ channels, were unaffected by tryptase. These findings show a striking promotion of agonist-induced bronchial smooth muscle contraction by mast cell tryptase, via direct or indirect effects on Ca2+ channels, and the findings therefore suggest a novel potential mechanism of hyperresponsiveness in dog bronchi. an inhibitor of tryptase (a major protease released with histamine from secretory granules of mast cells). The potentiation of histamine-induced contractions was reproduced by active tryptase in pure form. The contractions due to the combination of histamine and purified tryptase were abolished by the (a2+ channel blockers nifedipine and verapamil. The bronchoconstricting effects of KCI and serotonin, which, like histamine, contract airway smooth muscle by a mechanism predominantly involving membrane potential-dependent Ca2+ transport, were also potentiated by tryptase. However, the contractile effects of acetylcholine, which contracts dog airway smooth muscle by a mechanism independent of Ca2`channels, were unaffected by tryptase. These findings show a striking promotion of agonistinduced bronchial smooth muscle contraction by mast cell tryptase, via direct or indirect effects on (a2+ channels, and the findings therefore suggest a novel potential mechanism of hyperresponsiveness in dog bronchi.
Introduction
Mast cells are believed to participate in asthma via release of preformed and newly formed mediators which contract smooth muscle. However, the bronchoconstrictor response to inhaled mast cell-derived mediators such as histamine is greater in asthmatic subjects than in normal individuals. Thus, a key ingredient for asthmatic responses to bronchoactive mediators is hyperresponsiveness, but its pathogenesis is not understood (1) . The present study was stimulated by the observation that supernatants obtained by degranulation of dog mastocytoma cells greatly increase the contractile responses of dog bronchi to histamine (2) . Because dog mastocytoma cells (3) , like mast cells of human lung (4) , release neutral serine proteases along with other preformed mediators during deDr. Sekizawa To inhibit the release of cyclooxygenase and lipoxygenase products, the cells were preincubated with BW755C (10-4 M; 30 min) (7, 8) . The cells were then incubated with Ca2+ ionophore (3. 10-6 M; 20 min) at 4°C, washed three times with Ca2+-free, Mg2+-free Tyrode's buffer at 4°C, and resuspended in 3 ml of complete Tyrode's buffer at 37°C. After incubation for 30 min, the reaction was stopped by reducing the temperature to 4°C, the tubes were centrifuged at 200 g for 10 min, and the supernatants were used for analysis of histamine and protease content and for studies in muscle baths. Supernatants were prepared in batches, and each series of experiments used supernatant from the same batch.
Purification oftryptase. Tryptase was purified from BR dog mastocytoma cells as described previously (9) . Tryptase activity in mastocytoma degranulation supernatants and in purified preparations was measured spectrophotometrically with the chromogenic substrate benzoyl-L-val-gly-arg-4-nitroanilide (9) .
Assay of histamine. Histamine in supernatants and muscle bath bathing fluid was measured spectrofluorometrically (10) Effect of protease inhibitor and histamine H,-receptor antagonist on mastocytoma degranulation supernatant-induced contraction of dog bronchi. The active tension was recorded from bronchi in a 14-ml muscle bath containing 1 ml of dog mastocytoma degranulation supernatant. Supernatant was preincubated with 30 ,ug/ml aprotinin, an inhibitor of dog tryptase, before incubation with bronchi (five dogs). Control tissues were incubated with supernatant preincubated for 30 min without aprotinin (five dogs). In separate experiments (nine dogs), bronchi contracted with mastocytoma supernatant ("supernatant alone") were ihen exposed to the HI-receptor antagonist pyrilamine (10-5 M) to measure the response to H,-receptor blockade ("supernatant plus pyrilamine"). All data expressed as means±SEM.
Results
Bronchomotor responses to mastocytoma degranulation supernatant. When muscle was preincubated with mastocytoma supernatant, the histamine response curve was shifted strikingly to the left, and the maximum tension achieved was greater than the response to exogenous histamine alone. These augmented contractile responses to histamine were dependent on the dilution of the added supernatant (Fig. 1) . In these studies, the concentration of histamine in the muscle bath in the presence of 1 ml of undiluted supernatant was 3-10-6 M. The supernatant-induced contractions were inhibited by the H1-receptor antagonists pyrilamine (l0-5 M; 0.7±0.5% of control; n = 9; P < 0.01) (Fig. 2) and diphenhydramine (IO-' M; 0.0±0.0% of control; n = 6; P < 0.01) with IC50's of 0.63±0.21* 10-6 M and 0.25±0.06-10-6 M, respectively. In contrast, supernatant-induced contractions were increased by the H2-receptor antagonist metiamide (10-5 M; 125.3±7.3% of control; P < 0.05). These studies indicated that an ingredient of the mastocytoma supernatant potentiates histamine-induced contractions in a concentration-dependent manner via an H1-receptor.
Because dog BR mastocytoma cells release the serine protease tryptase into degranulation supernatants (3), we tested the effects of the protease inhibitor aprotinin on supernatantinduced bronchial smooth muscle contraction. Aprotinin inhibits purified dog mastocytoma tryptase (9) but has no effect on purified chymase (11), the other major secretory seine protease of mast cell granules. Muscle bath fluid with 1 ml of undiluted supernatant contained 90 ng/ml ofactive tryptase in these experiments. In pilot studies we confirmed that aprotinin incubated with mastocytoma supernatant selectively inhibits the amidolytic activity of tryptase without affecting chymase (data not shown). Preincubation ofsupernatant with aprotinin markedly decreased bronchial smooth muscle contraction caused by supernatant compared to the responses after preincubation of supernatant without aprotinin ( Fig. 2 ): 1 ml of supernatant preincubated with aprotinin produced tension of only 14.2±3.2 g/g tissue weight compared to 99.3±14.7 g/g tissue weight produced by supernatant preincubated without aprotinin (P < 0.05). The response in the presence ofaprotinin is similar to the tension expected from histamine alone in the muscle bath (-15 g/g tissue weight, obtained by extrapolation of data from the histamine-response curve given in Fig. 1 ). These effects of aprotinin suggested that tryptase may be the ingredient in mastocytoma supernatants which augments histamine-induced bronchial smooth muscle contraction. Bronchomotor responses to puriied tryptase. To establish more definitively the role of tryptase suggested by the supernatant experiments, we studied the actions of highly purified tryptase in the muscle bath. Tryptase, in a concentration matching that in the supernatant bath (90 ng/ml), did not affect resting tension, and neither heparin alone nor the vehicle for tryptase alone had an effect on the histamine concentration-response curve (P > 0.5). However, tryptase caused a marked leftward shift ofthe histamine concentration-response curve, decreasing the ED50 for histamine, and also increased the maximum tension after histamine ( Fig. 3 and Table I ). These effects were similar to those produced by the supernatant containing identical tryptase activity. Smooth muscle contractile responses at a fixed concentration of histamine (10-6 M) increased with increasing concentrations of tryptase in the bath (Fig. 4) .
Because proteases may release mast cell histamine (12), we studied the effect of tryptase on the histamine content in the smooth muscle chamber. Incubation of bronchial rings with tryptase (90 ng/ml) increased the histamine content in the bathing medium slightly but not significantly (from 0.43±0.28* 10-8 M to 6.30±2.80. 10-8 M; n = 6, P > 0.05). These concentrations of histamine did not contract bronchial muscle in the bath (Fig. 1) and therefore can not explain the tryptase-induced muscle effects. Furthermore, the increased responses after tryptase were not mimicked by concentrations of histamine as high as 10-3 M (Fig. 1) , and tryptase alone did not increase resting tension, as would be expected if significant concentrations of histamine were released.
Serotonin and KCI, like histamine, contract dog airway smooth muscle predominantly via Ca2l transport through voltage-dependent channels (13) (14) (15) . We found that the responses of dog bronchi to serotonin and KCI, like those to histamine, were also potentiated by tryptase (Table I) . Thus, in five dogs, the ED50 for serotonin was decreased by tryptase and the maximum contraction produced by serotonin was increased. In five dogs, tryptase also markedly increased the active tension produced by KC1 (2. 10-5 M; Table I ).
In separate experiments in five dogs, the time course of tryptase potentiation of KCl-induced contraction was examined. After incubation of muscle with tryptase (90 ng/ml), (13, 14) , a mechanism that differs from that of histamine, serotonin and KC1 (14, 15) , we studied the effect of tryptase (90 ng/ml) on the concentrationresponse curve to acetylcholine. In five dogs, the ED50 for acetylcholine and the maximum tension produced by acetylcholine were unaffected by tryptase (Table I ). These findings demonstrate that the potentiating effects of tryptase extend to other agonists which contract smooth muscle by stimulating Ca2' transport via voltage-dependent channels, but do not extend to acetylcholine, which contracts smooth muscle by a different mechanism.
To further investigate the possibility that tryptase-augmented muscle contraction is mediated via an influence on Ca2+ channels, we studied the effects of verapamil and nifedipine, which block that portion of Ca 2 influx which is due to membrane depolarization in smooth muscle (16) . We found that verapamil and nifedipine reverse the large contractions produced by the combination of tryptase (90 ng/ml) and histamine (l0-5 M) with IC50 values of 0.59±0.27 * 10-6 M and 0.12±0.04-10-6 M, respectively, and that both Ca2' channel blockers reversed the contractions completely at concentrations of 10-5 M (Fig. 5) .
Discussion
The marked potentiation of histamine-induced bronchial contraction by mastocytoma degranulation supernatants demonstrates a novel and potentially important interaction between mast cell products and airway smooth muscle. The similar smooth muscle responses to tryptase-containing supernatant and to matching concentrations of pure tryptase suggest that the principal ingredient responsible for supernatant effects is tryptase. Because supernatant-augmented histamine contractions were abolished by an inhibitor of tryptase, it is likely that the effects require catalytically active enzyme. The persistent augmentation of KCl-induced contractions after removal of tryptase from the muscle bath is consistent with a mechanism involving proteolytic cleavage rather than simple binding; the return to the control state indicates that the action of tryptase does not involve irreversible membrane damage.
The observation that tryptase potentiates the contractile effects of histamine, serotonin, and KCI suggests that the enzyme exerts its effects at a point in the stimulus-contraction pathway shared by the three chemically distinct agonists. Because the smooth muscle effects ofthese three agonists depend on the movement of external Ca2" into the cell, and because Ca2" channel blockers abolish contractions induced by the combination of tryptase and histamine, we suggest that tryptase may affect airway smooth muscle responsiveness by modifying Ca2" channels. This hypothesis is supported by the failure of tryptase to augment the contractions produced by acetylcholine, a bronchoconstricting agonist whose smooth muscle effects are mediated by a mechanism independent of voltage-dependent Ca2" channels. Tryptase could affect the channel itself. Alternatively, it could cleave a regulatory protein on the cell surface. More studies are needed to investigate these possibilities and to determine the molecular basis of the action of tryptase on airway smooth muscle.
The relevance in vivo of the levels of tryptase used in the muscle bath is difficult to establish with certainty. However, the highest concentration used (90 ng/ml) is within the range of those detected in the serum of patients with systemic anaphylaxis or mastocytosis (17) . The predominance of tryptase in lung mast cells (18) adds to the likelihood that this enzyme may play an etiologic role in airway smooth muscle hyperresponsiveness. Human airways contain 33 ,ug of tryptase per cm3 in the submucosa of segmental bronchi, assuming a mast cell density of 3 . 106 cells per cm3 (19) and 11 Mug of tryptase per 106 cells (18) . Therefore, the concentration of tryptase in human airway tissue is 2-3 orders of magnitude greater than the concentration used in these experiments.
Several previous studies provide evidence of airway hyperresponsiveness in vivo in dogs inhaling 03 (20) , leukotriene B4 (21), or allergen (22) . These stimuli all result in the release of thromboxane, which in turn increases bronchomotor responses via vagal motor pathways (23) . Effects of thromboxane and tryptase differ as follows: (a) thromboxane causes a small shift to the left in the response to electrical field stimulation (23) , while tryptase causes a striking leftward shift and an increase in maximum tension in response to agonists (histamine, serotonin, KCl) that cause contraction via Ca2+ channels; (b) thromboxane acts through pre-or postsynaptic effects on motor nerves which then release acetylcholine, while our evidence suggests that tryptase may act on smooth muscle to affect voltage-dependent Ca2" channels. 
